权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Functional characterization of the Alzheimer's disease Epigenome

阿尔茨海默病表观基因组的功能表征

基本信息

批准号：
10414137
负责人：
Michael Ryan Corces
金额：
$ 24.9万
依托单位：
J. DAVID GLADSTONE INSTITUTES
依托单位国家：
美国
项目类别：
财政年份：
2018
资助国家：
美国
起止时间：
2018-07-15 至 2023-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10414137
关键词：
3-Dimensional ATAC-seq Affect Age Alzheimer&apos s Disease Architecture Award Biological Assay Brain Brain Diseases Brain region CRISPR interference Chemicals Chromatin Clinical Clustered Regularly Interspaced Short Palindromic Repeats Code Communities Complement DNA Data Data Set Disease Elements Enhancers Epigenetic Process Evaluation Foundations Freezing Funding Genes Genetic Genetic Polymorphism Genotype Growth Heart Diseases Heritability Human Impaired cognition Incidence Individual Institution Intervention Investigation Knowledge Laboratories Late Onset Alzheimer Disease Lead Learning Link Maps Mentors Mentorship Methods Mind Modification Molecular Mutation Nerve Degeneration Neurobiology Neurodegenerative Disorders Nucleic Acid Regulatory Sequences Pathogenesis Pathologic Patients Phase Play Prevention Public Health Regulator Genes Regulatory Element Research Risk Role Single Nucleotide Polymorphism Techniques Testing Therapeutic Therapeutic Intervention Time Tissues Training Translating United States Universities Untranslated RNA Validation Work age related age related neurodegeneration aging brain autosomal dominant Alzheimer&apos s disease base brain cell cell type cognitive function comorbidity data visualization disease-causing mutation epigenome epigenomics gene discovery genome wide association study healthy aging insight lifetime risk medical schools mortality novel online resource patient subsets presenilin-1 presenilin-2 prevent progressive neurodegeneration promoter resilience risk variant skills targeted treatment web portal

项目摘要

PROJECT SUMMARY / ABSTRACT Alzheimer’s disease (AD) manifests as a devastating age-related progressive neurodegeneration. This neurodegeneration and the concomitant loss of cognitive function plagues more than 44 million individuals worldwide. Our understanding of the molecular pathogenesis of AD remains incomplete and no therapies exist to prevent, stop, or cure the associated neurodegeneration. This marks one of the greatest unmet clinical needs of our time. Through decades of research, genome-wide association studies have identified heritable coding and non-coding mutations that lead to an increased risk of developing AD. Many of these mutations, however, remain largely under-characterized and their contribution to AD pathogenesis remains unclear. Moreover, it has become increasingly clear that an individual’s lifetime risk of developing AD is not merely governed by genetics. In addition, the epigenome, the complement of all of the chemical and physical modifications imposed on DNA that do not change the underlying sequence, is also thought to play a crucial role. This project aims to define the epigenetic (Aim 1) and genetic (Aim 2) components of AD through profiling of the open chromatin landscapes and three-dimensional chromatin interactions in brain regions and primary cell types of patients with and without AD. These characterizations will identify key AD-related regulatory elements that will be functionally validated with CRISPR interference tiling assays (Aim 3). Taken together, this project will provide an unprecedented picture of the AD epigenome, identifying novel aspects of AD pathogenesis and nominating putative avenues for therapeutic intervention. This work will be performed under the co-mentorship of Dr. Howard Chang, an expert in the application of epigenomics to disease, and Dr. Thomas Montine, a leader in brain aging and AD, at the Stanford University School of Medicine, a world-class research institution. Aims 1 and 2 will be performed predominantly during the K99 mentored phase while Aims 3 and 4 will be performed predominantly during the R00 independent phase. If funded, this award will allow me to pursue a rigorous training plan in neurobiology and age-related neurodegeneration, enabling me to expand my research in new directions, learn new techniques, and acquire the knowledge and skills to establish an independent laboratory focused on the epigenetics of AD.

项目总结/摘要阿尔茨海默病（AD）表现为一种破坏性的与年龄相关的进行性神经变性。这神经变性和随之而来的认知功能丧失困扰着超过4400万人国际吧我们对AD的分子发病机制的理解仍然不完全，也没有治疗方法来预防、阻止或治愈相关的神经退化。这标志着最大的未满足的临床需求之一我们这个时代。通过几十年的研究，全基因组关联研究已经确定了遗传编码，非编码突变导致AD风险增加。然而，许多这些突变仍然存在，在很大程度上特征不足，它们对AD发病机制的贡献仍不清楚。此外，它已成为越来越清楚的是，一个人一生中患AD的风险不仅仅是由遗传决定的。在此外，表观基因组是对DNA施加的所有化学和物理修饰的补充，不改变潜在的序列，也被认为发挥了至关重要的作用。该项目旨在定义通过分析开放染色质景观，研究AD的表观遗传（Aim 1）和遗传（Aim 2）成分和三维染色质的相互作用，在大脑区域和原代细胞类型的患者， AD.这些特征将确定关键的AD相关的调控元件，这些元件将在功能上得到验证 CRISPR干扰平铺测定（Aim 3）。总的来说，这个项目将提供前所未有的 AD表观基因组的图片，确定AD发病机制的新方面，并提名公认的途径，治疗干预这项工作将在应用专家霍华德·张博士的共同指导下进行以及斯坦福大学的托马斯·蒙廷博士，他是大脑衰老和AD领域的领导者医学院，世界一流的研究机构。目标1和2将主要在2010年期间执行。 K99指导阶段，而目标3和4将主要在R 00独立阶段执行。如果这个奖项将使我能够在神经生物学和年龄相关的严格培训计划神经变性，使我能够在新的方向上扩展我的研究，学习新的技术，并获得知识和技能，建立一个独立的实验室，专注于AD的表观遗传学。